Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights
Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI)
Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027
LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) ('Mereo' or the 'Company'), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided recent corporate highlights.
'As we close out the first quarter of 2025, we continue to anticipate that this will be an important, milestone-rich year for Mereo. The Phase 3 Orbit study of setrusumab in osteogenesis imperfecta remains on track to read-out either at the second interim analysis in mid-2025 or at the final analysis in the fourth quarter. We are continuing to invest in the pre-commercial activities for setrusumab to enable a successful launch in our European territory, following potential regulatory approvals,' said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. 'Further, alvelestat is now Phase 3 ready and we are finalizing the trial start-up activities to support our ongoing partnering process. Along with our late-stage pipeline, we believe that continued close management of our cash balance will enable us to support our operations into 2027.'
First Quarter 2025 Highlights, Recent Developments, and Anticipated Milestones
Setrusumab (UX143)
Alvelestat (MPH-966)
First Quarter 2025 Financial Results
Total research and development ('R&D') expenses decreased by $0.1 million from $4.0 million in the first quarter of 2024 to $3.9 million in the first quarter of 2025. The decrease was primarily due to decreases of $1.2 million and $0.1 million in R&D expenses for alvelestat and etigilimab, offset by an increase of $1.3 million in R&D expenses for setrusumab. The decrease in program expenses for alvelestat was primarily due to undertaking reduced drug formulation and manufacturing activities in preparation for the Phase 3 study in the first quarter of 2025, compared to the first quarter of 2024. The increase in program expenses for setrusumab was primarily driven by amounts due under the manufacturing and supply agreement with our partner, Ultragenyx, ongoing activities related to real-world evidence programs and medical affairs activities in Europe and input into development, regulatory and manufacturing plans with Ultragenyx, who fund the global development of the program pursuant to our license and collaboration agreement.
General and administrative expenses increased by $1.4 million from $5.9 million in the first quarter of 2024 to $7.3 million in the first quarter of 2025. The increase was primarily due to the recognition of a $1.7 million reduction in expenses in the first quarter of 2024 for amounts received from our depository to reimburse certain expenses incurred by us in respect of our ADR program, partially offset by a net decrease in employee-related expenses and professional fees. A reimbursement in respect of our ADR program is anticipated in 2025.
Net loss for the first quarter of 2025 was $12.9 million, compared to $9.0 million during the first quarter of 2024, primarily reflecting an operating loss of $11.2 million and foreign currency translation loss.
As of March 31, 2025, the Company had cash and cash equivalents of $62.5 million, compared to $69.8 million as of December 31, 2024. The Company's guidance remains unchanged, and it continues to expect, based on current operational plans, that its existing cash and cash equivalents balance will enable it to fund its currently committed clinical trials, operating expenses, and capital expenditure requirements into 2027. This guidance does not include any potential upfront payments associated with a partnership for alvelestat or business development activity around any of the Company's non-core programs.
Total ordinary shares issued as of March 31, 2025 were 795,001,444. Total ADS equivalents as of March 31, 2025 were 159,000,288, with each ADS representing five ordinary shares of the Company.
About Mereo BioPharma
Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI); and alvelestat for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). The Company's partner, Ultragenyx Pharmaceutical, Inc., has completed enrollment in the Phase 3 portion of a pivotal Phase 2/3 study in pediatrics and young adults (5 to 25 years old) for setrusumab in OI and in the Phase 3 study in pediatric patients (2 to <7 years old). The partnership with Ultragenyx includes potential additional milestone payments of up to $245 million and royalties to Mereo on commercial sales in Ultragenyx territories. Mereo has retained EU and UK commercial rights and will pay Ultragenyx royalties on commercial sales in those territories. Setrusumab has received orphan designation for osteogenesis imperfecta from the European Commission ('EC') and the FDA, PRIME designation from the EMA, and has Breakthrough Therapy designation and rare pediatric disease designation from the FDA. Alvelestat has received Orphan Designation for AATD from the EC and the FDA, and Fast Track designation from the FDA for AATD-LD. Following results from ASTRAEUS and ATALANTa in AATD-lung disease, the Company has aligned with the FDA and the EMA on the primary endpoints for a Phase 3 pivotal study which, if successful, could enable full approval in both the U.S. and Europe. In addition to the rare disease programs, Mereo has two oncology product candidates, etigilimab, an anti-TIGIT; and navicixizumab for the potential treatment of late-line ovarian cancer. Navicixizumab has been partnered with Feng Biosciences, Inc. in a global licensing agreement that includes milestone payments and royalties. Mereo has also entered into an exclusive global license agreement with ReproNovo SA, a reproductive medicine company, for the development and commercialization of leflutrozole, a non-steroidal aromatase inhibitor.
Forward-Looking Statements
This press release contains 'forward-looking statements' that involve substantial risks and uncertainties. All statements other than statements of historical fact contained herein are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements usually relate to future events and anticipated revenues, earnings, cash flows or other aspects of our operations or operating results. Forward-looking statements are often identified by the words 'believe,' 'expect,' 'anticipate,' 'plan,' 'intend,' 'foresee,' 'should,' 'would,' 'could,' 'may,' 'estimate,' 'outlook' and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates.
All of the Company's forward-looking statements involve known and unknown risks and uncertainties some of which are significant or beyond its control and assumptions that could cause actual results to differ materially from the Company's historical experience and its present expectations or projections. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical development process; the Company's reliance on third parties to conduct and provide funding for its clinical trials; the Company's dependence on enrollment of patients in its clinical trials; and the Company's dependence on its key executives. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the Company's business, including those described in the 'Risk Factors' section of its Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of our forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.
Mereo BioPharma Contacts:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Dozens seek help at rail station mental health hub
Dozens of people have been accessing mental health support at a railway station centre in its first month. "The Hub" was launched by West Midlands Railway (WMR) and charity Rethink Mental Illness at Wolverhampton Station, in May. It is providing people with support and guidance, as well as offering a space for local organisations to run pop-ups and events. "The Hub has been extremely successful in its first four weeks of opening," said Samantha Passmore, Wolverhampton customer experience manager for WMR. "We have had dozens of people enquiring about advice and additional support, and more and more charities are requesting to use the facility, which was our vision from day one. "We look forward to seeing the Hub go from strength to strength over the coming months." Organisations already using the site have included employment support service Thrive into Work, and Children in CueSports - which provides pathways into sport. "In just a few weeks, we've seen how much of a difference it can make to have an accessible space where people feel able to reach out for help," said Kirsten Rose, service manager at Rethink Mental Illness - which maintains and staffs the site. "It's a great example of what's possible when organisations come together to put mental health at the heart of local communities." The initiative is backed by Black Country Healthcare NHS Foundation – the lead provider of mental health and learning disability services in the region. Its chief nurse Carolyn Green, said they had seen increased interest in their services since the hub opened. "This includes our 24/7 mental health helpline, our sanctuary hubs, the Black Country Recovery College, and free suicide prevention training for families and carers," she said. "Having somewhere that signposts to these services in a visible, public location really matters and we believe it is, and will continue to be, life-saving." Follow BBC Wolverhampton & Black Country on BBC Sounds, Facebook, X and Instagram. Hub aims to help rail passengers in crisis Former radio station studio up for auction West Midlands Railway
Yahoo
35 minutes ago
- Yahoo
Is this penny stock on track for an explosive recovery in 2025?
Penny stocks have a well-earned reputation for being volatile. But these tiny businesses are also capable of potentially delivering explosive gains. And investors who snapped up shares in IG Design Group (LSE:IGR) a month ago are already experiencing some of this first-hand. The gift and celebration packaging company has just kicked off a turnaround strategy that's started yielding some positive results. This has helped repark some fresh investor sentiment, sending the share price up more than 40% in the last month alone, with a 34% gain in a single day at the end of May. Despite this surge, the IG Design share price is still trading significantly lower compared to a year ago. That means there's still a long way to go for the business to complete its recovery. Yet, if analyst forecasts are correct, that could soon change. A big part of renewed investor sentiment is management's decision to exit DG America's business. Despite generating close to $500m in revenue, the segment has struggled to deliver a profit. And with US tariffs only adding more pressure, leadership concluded that the 'headwinds facing the division are untenable'. The decision to dispose of problematic DG America was met with praise from investors. Why? Because the company's now significantly reduced its exposure to the weaker US retail market environment that it's struggled to navigate. At the same time, IG Design has just freed up a lot more capital to reinvest in stronger areas, refocusing the business into more profitable ventures. Subsequently, profit margins and free cash flow generation are expected to rise. And institutional analysts have revised their earnings per share forecasts for 2026 to reach $0.43 versus the $0.16 achieved in 2024 – a 170% improvement. Obviously, there's no guarantee that this target will be hit since we're still in the early stages of its turnaround plan. But if it does get things back on track, the team at Research Tree think the penny stock could skyrocket by 120% to 198p by this time next year! No investment's ever risk-free, and that's especially true for IG Design Group. Despite being the source of many of its problems, DG America was also responsible for around half of its revenue stream. The company's now dependent predominantly on the UK, European, and Australian markets, which have their own fair share of challenges. A big source of renewed investor sentiment is IG Design's ability to rebuild its scale at a higher margin in these markets. But a failure of execution could douse the flames of optimism and send the penny stock tumbling back down in the wrong direction. Even if management makes all the right moves, there's still the consumer spending cycle that can throw a spanner in the works. IG Design's product portfolio consists entirely of discretionary items which aren't likely to be in high demand if economic conditions take a turn for the worse – something that's completely out of management's control. All things considered, I'm cautiously optimistic and think investors comfortable with high-risk, high-reward ventures may want to consider taking a closer look. The post Is this penny stock on track for an explosive recovery in 2025? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Sign in to access your portfolio
Yahoo
35 minutes ago
- Yahoo
Does the Arbuthnot or the NatWest share price offer the best value?
NatWest Group (LSE:NWG) and Arbuthnot Banking Group (LSE:ARBB) are two UK-listed banks with very different profiles but both attracting investor interest. With the NatWest shares price surging, I want to look at other options. So let's break down their forward valuations and dividend prospects to see which might offer better value for 2025 through 2027. NatWest's forward price-to-earnings (P/E) ratio is expected to fall from 9.18 times in 2025 before falling back to 8.24 times in 2026 and 7.54 times in 2027. This reflects a continued earnings growth as the macroeconomic situation improves. Arbuthnot, on the other hand, has a P/E falling from 7.37 times in 2025, then declining to 6.28 times in 2026 and 5.49 times in 2027. Arbuthnot's lower multiples suggest it's trading at a discount relative to NatWest, though its earnings are less predictable. NatWest's dividend per share is forecast to increase from 17p in 2024 to 29p in 2025, 32p in 2026, and 36p in 2027, translating to a dividend yield rising from 5.35% to 6.84%. Its payout ratio is steady around 40-51%, indicating a balanced approach between rewarding shareholders and retaining capital. Arbuthnot's dividends are expected to fall from 2024 — an exceptional year at 69p — falling to 53p in 2025, and then rising to 57p in 2026, and 61p in 2027, with the yield reaching 6.39% at the end of the period. Its payout ratio's expected to fall from 45% in 2024 to 35% in 2027. NatWest's price-to-book-ratio (PBR) is forecast to rise from 0.82 times in 2024 to 1.12 times in 2025. It then eases to 0.96 times in 2027, showing growing investor confidence. Arbuthnot's PBR's lower, around 0.54 times in 2024 with no onward forecast. Both banks trade at similar enterprise value-to-revenue multiples near 0.8–0.85 times in 2025, indicating comparable market pricing relative to revenues. NatWest benefits from a strong capital position, improving net interest margins, and a supportive UK banking environment, driving steady earnings growth. Arbuthnot, a smaller, more niche player, also shows rapid revenue growth but more earnings volatility, which may appeal to investors seeking higher risk and reward. Arbuthnot looks slightly cheaper, based on forward earnings metrics, despite having a marginally lower dividend yield. I would however, suggest that the lower payout ratio could lead to faster dividend growth. Personally, I favour the AIM-listed bank. However, I appreciate that being AIM listed, it may be easily overlooked by investors. Coupled with its smaller size, it may continue to trade at a discount to larger peers. I believe investors should consider both stocks, and decide which is right for their portfolios. However, my choice is Arbuthnot, and I've recently opened a small position in the bank. The post Does the Arbuthnot or the NatWest share price offer the best value? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool James Fox has no position in Arbuthnot Banking Group PLC. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025
